Anti-Scl-70 antibodies, also known as Anti-Topoisomerase I antibodies, are a specific type of autoantibody primarily associated with systemic sclerosis (scleroderma), a chronic autoimmune disease. These antibodies target the enzyme topoisomerase I, which is involved in DNA replication and repair. The presence of Anti-Scl-70 antibodies is clinically significant as they are found in approximately 20-40% of patients with systemic sclerosis, particularly in those with the diffuse cutaneous form of the disease.
Testing for these antibodies is often conducted as part of the diagnostic process for scleroderma, as their presence can indicate a more severe disease course with a higher likelihood of internal organ involvement, such as interstitial lung disease and renal crisis. The "RDL" in the context likely refers to a specific laboratory or testing method used for detecting these antibodies. Detection of Anti-Scl-70 antibodies is usually done through methods like ELISA, immunofluorescence, or Western blotting. However, it's important to note that the presence of these antibodies alone is not sufficient for a diagnosis of scleroderma; clinical symptoms and other diagnostic criteria must also be considered.
Anti-Scl-70 Ab (RDL)
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.